Trial Profile

Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; VE 800 (Primary) ; Vancomycin
Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Malignant melanoma; Oesophageal cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms Consortium-IO
Sponsors Vedanta Biosciences

Most Recent Events

07 Nov 2024 According to Florida Cancer Specialists & Research Institute media release, results from this study being presented this week at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston.
16 Mar 2023 Status changed from active, no longer recruiting to completed.
21 Jul 2021 According to a Vedanta Biosciences media release, company is nearing completion of Stage 1 of this trial, and also plans to present the results at a future medical conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com